This review found that addition of rituximab to chemotherapy regimens for stage III-IV follicular lymphoma showed an improvement in clinical outcomes with minimal clinically relevant extra adverse events or toxicity. This was a generally well-conducted review. The authors' conclusions reflect the evidence presented and appear reliable.
Study selection
Randomised controlled trials (RCTs) that compared rituximab in combination with any of ten specified chemotherapy regimens with the same chemotherapy alone were eligible. Trials had to enrol patients with symptomatic stage III-IV follicular lymphoma who had not received any previous treatment. The primary outcome of interest was overall survival; secondary outcomes and response rates were listed in the report.
The included trials all involved different chemotherapy regimens. Median age ranged from 52 to 61 years and the proportion of men ranged from 37 to 55%. Co-interventions were given to both treatment groups in three of the trials.
Titles and abstracts were assessed by one reviewer. A sample of citations (10%) were checked by a second reviewer and any discrepancies resolved by discussion. Full texts of relevant items were selected for inclusion by one reviewer.
Assessment of study quality
Study quality was assessed using criteria based on those proposed by the Centre for Reviews and Dissemination for RCTs. Assessments were done by one reviewer and checked by a second.
Data extraction
Data were extracted by one reviewer and checked by a second. Discrepancies were resolved by discussion. For exploratory meta-analyses, data on numbers of patients and events in each group were used to derive relative risks and associated 95% confidence intervals.
Methods of synthesis
Data were tabulated and discussed in a narrative synthesis. Exploratory meta-analyses were performed for response rate outcomes using random-effects models. Heterogeneity in these analyses was explored qualitatively and using the Χ² test and Ι² statistic.
